Summary: The Centers for Medicare & Medicaid Services modified its coverage policy for cardiac output monitoring by thoracic electrical bioimpedance (TEB), effective May 15, 2026. Here's what changes for billing teams.
CMS's coverage policy for thoracic electrical bioimpedance monitoring has been updated. The full policy is tracked at PayerPolicy under the title "Cardiac Output Monitoring by Thoracic Electrical Bioimpedance (TEB)." The policy document does not list specific CPT or HCPCS codes in the available data — but the clinical scope is clear: non-invasive cardiac output measurement via TEB for Medicare beneficiaries. If your team handles cardiology, critical care, or internal medicine billing, this update is worth a close look before May 15, 2026.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Cardiac Output Monitoring by Thoracic Electrical Bioimpedance (TEB) |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | May 15, 2026 |
| Impact Level | Medium — coverage for TEB monitoring is frequently contested at the MAC level |
| Specialties Affected | Cardiology, critical care, internal medicine, pulmonology |
| Key Action | Audit your TEB claims and documentation against updated medical necessity criteria before May 15, 2026 |
CMS Cardiac Output Monitoring by Thoracic Electrical Bioimpedance Coverage Criteria and Medical Necessity Requirements 2026
CMS has maintained a historically skeptical position on thoracic electrical bioimpedance as a cardiac output monitoring method. The agency has generally treated TEB as investigational or of unproven clinical utility for most Medicare beneficiaries. That posture is at the core of any modification to this coverage policy.
The real issue here is medical necessity. CMS coverage policy decisions on TEB hinge on whether the clinical evidence supports routine use, and historically, that evidence bar has not been easy to clear. Expect the updated policy to reinforce — or possibly tighten — the conditions under which TEB monitoring qualifies for Medicare reimbursement.
Because the full policy document was not available in the source data, the specific updated medical necessity criteria cannot be quoted verbatim here. Your billing team should pull the full policy text directly from the CMS source before May 15, 2026. You can access the tracked version at PayerPolicy's record for this policy.
What we do know from the policy title and CMS's established pattern on this technology: TEB monitoring faces a high documentation burden to prove medical necessity. Your clinical team needs to link the monitoring directly to a covered clinical indication — not just order it as a general hemodynamic assessment tool.
Prior authorization may not be required at the national level for all TEB claims, but your Medicare Administrative Contractor (MAC) may have its own local coverage determination (LCD) that adds requirements on top of the national policy. Check with your MAC before assuming the national CMS policy is the only hurdle.
If you're billing for TEB in a hospital outpatient, office, or critical care setting, the documentation requirements likely differ by place of service. That distinction matters for claim submission and for defending medical necessity in a post-payment audit.
CMS Thoracic Electrical Bioimpedance Exclusions and Non-Covered Indications
CMS has historically treated TEB as investigational for broad cardiac output monitoring applications. That classification drives most of the claim denial risk in this space.
The general CMS position — consistent across earlier versions of this policy — is that TEB monitoring lacks sufficient clinical evidence to support coverage as a routine cardiac monitoring tool for most Medicare patients. That doesn't mean zero coverage. It means the bar for what qualifies is narrow.
Conditions likely to remain non-covered or experimental include: routine hemodynamic monitoring without a documented clinical indication tied to a specific covered diagnosis, use as a screening tool rather than a diagnostic or management aid, and situations where invasive cardiac output measurement is considered the clinical standard but TEB is substituted for convenience or cost reasons.
Again — without the full policy text in hand, your compliance officer should review the specific exclusion language in the updated document. If you're not sure how your patient mix maps to the updated criteria, talk to your compliance officer before May 15, 2026.
Coverage Indications at a Glance
The policy data does not include specific coded indications with coverage status. The table below reflects what CMS has historically applied to TEB monitoring coverage decisions. Treat this as a starting framework — not a substitute for the full policy text.
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| TEB for cardiac output monitoring with documented clinical indication | Likely covered when criteria met | Not specified in source data | Medical necessity documentation required |
| TEB as routine or screening hemodynamic monitoring | Likely not covered | Not specified in source data | CMS has treated this as investigational in prior versions |
| TEB when invasive monitoring is clinical standard of care | Likely not covered | Not specified in source data | Substitution without clinical justification will not meet medical necessity |
| TEB in conjunction with covered cardiac management for a documented diagnosis | Requires review | Not specified in source data | Check MAC LCD for regional coverage determinations |
Pull the full policy before billing. The table above reflects historical CMS patterns, not the specific text of the May 2026 modification.
CMS Thoracic Electrical Bioimpedance Billing Guidelines and Action Items 2026
Here's what your billing team should do now. Work through this list before May 15, 2026.
| # | Action Item |
|---|---|
| 1 | Pull the full updated policy text immediately. Access the CMS policy at https://app.payerpolicy.org/p/cms/267-v3 and get the complete current criteria. Do not rely on your existing documentation templates until you've confirmed what changed. |
| 2 | Check your MAC's LCD for TEB monitoring. CMS national coverage policy sets the floor, but your Medicare Administrative Contractor may have a local coverage determination with stricter or more specific criteria. If your MAC has an LCD on cardiac output monitoring or TEB specifically, that LCD governs your claims — not just the national policy. |
| 3 | Audit open TEB claims submitted before May 15, 2026. If you have claims in process, confirm they're documented to the standard in the prior policy version. Claims submitted after the effective date of May 15, 2026 will need to meet the updated criteria. |
| 4 | Update your documentation templates. Work with your clinical team to revise the documentation requirements for TEB monitoring orders. Every TEB claim needs a clear link between the monitoring and a specific covered clinical indication. Vague documentation is the fastest path to a claim denial. |
| 5 | Flag TEB billing for additional review in your RCM workflow. Given CMS's history of treating this technology skeptically, TEB monitoring billing carries above-average audit risk. Add a manual review step before submission for any claim involving cardiac output monitoring. |
| 6 | Train your coders on the updated criteria. If the modification changes which indications are covered or adds new documentation requirements, your coding team needs to know before the effective date — not after the first denial lands. |
| 7 | Evaluate your payer mix beyond Medicare. Commercial payers often align with CMS on technology assessments like TEB. If Aetna, Cigna, or UnitedHealthcare follow a similar coverage policy for TEB in your contracts, this CMS modification may signal similar updates from commercial plans in the coming months. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Cardiac Output Monitoring by Thoracic Electrical Bioimpedance
The policy data provided for this CMS coverage policy modification does not include specific CPT, HCPCS, or ICD-10 codes. This is not unusual for national-level CMS policy documents, which sometimes reference codes in attachments or related LCDs rather than the primary policy text.
Do not use codes found in generic coding resources without confirming they align with this specific policy. The risk of billing with the wrong code — or a code that isn't recognized under the CMS coverage policy for TEB — is a claim denial and potential compliance exposure.
How to Find the Applicable Codes
Your coding team should take three steps:
First, review the full policy document at the CMS source. The complete text may include a list of covered or non-covered codes not captured in the summary data.
Second, query your MAC's LCD for cardiac output monitoring or thoracic electrical bioimpedance. MACs often publish billing articles alongside LCDs that list the specific codes accepted for reimbursement under that determination.
Third, check the CMS National Correct Coding Initiative (NCCI) edits for any cardiac monitoring codes you currently use. If you've been billing TEB under a general monitoring code, confirm that code-level coverage still applies after May 15, 2026.
If your team identifies the applicable codes from the full policy or your MAC's LCD, update your charge capture immediately and test your claim scrubber against the new criteria before the effective date.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.